{"id":13315,"date":"2010-09-21T11:30:00","date_gmt":"2010-09-21T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/l%c2%92antitrust-multa-bracco-per-pubblicita-ingannevole\/"},"modified":"2010-09-21T11:30:00","modified_gmt":"2010-09-21T09:30:00","slug":"l%c2%92antitrust-multa-bracco-per-pubblicita-ingannevole","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/l%c2%92antitrust-multa-bracco-per-pubblicita-ingannevole\/","title":{"rendered":"The Antitrust fines Bracco for misleading advertising"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" height=\"126\" alt=\"\" width=\"180\" src=\"http:\/\/www.farmaplanet.it\/imgprd\/900887528.jpg\" \/><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><font size=\"3\"><font face=\"Calibri\">The Antitrust condemns the Bracco group to pay a 150 thousand euro fine for misleading advertising. In more detail, the Competition Authority accuses the Italian pharmaceutical company of having distributed advertising brochures, deemed untruthful, intended for medical personnel concerning two food supplements (Cogiton and Stenovit). The report was made by competitor Sharper Healthcare. <span style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin\">\u00ab<\/span>For both products - reports the Antitrust - the conditions of effectiveness on the prevention and treatment of brain aging and diseases related to cellular neurodegeneration as well as cardiovascular diseases are considered misleading<span style=\"mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin\">\u00bb<\/span>. In practice, according to the competition authority, both products mislead the recipients about the real characteristics and effects of its use.<\/font><\/font><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><font size=\"3\"><font face=\"Calibri\"><\/p>\n<p><em>Milan&amp;Finance \u2013 21 September 2010<\/em><\/p>\n<p><\/font><\/font><\/p>","protected":false},"excerpt":{"rendered":"<p>L&rsquo;Antitrust condanna il gruppo Bracco a pagare una multa da 150mila euro per pubblicit&agrave; ingannevole. Pi&ugrave; in dettaglio, l&rsquo;Autorit&agrave; garante per la concorrenza accusa la societ&agrave; farmaceutica italiana di aver diffuso opuscoli pubblicitari, ritenuti poco veritieri, destinati al personale medico che riguardavano due integratori alimentari (Cogiton e Stenovit). La segnalazione &egrave; stata fatta dalla concorrente &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13315"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13315\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}